Gilead poach­es new phar­ma de­vel­op­ment and man­u­fac­tur­ing chief from cell ther­a­py 2.0 play­er

Gilead has raid­ed one of the up-and-com­ing cell ther­a­py 2.0 biotechs to find its new head of phar­ma de­vel­op­ment and man­u­fac­tur­ing.

Dan O’Day’s phar­ma play­er has re­cruit­ed Stacey Ma from Sana Biotech­nol­o­gy for the se­nior ex­ec­u­tive team. A Genen­tech vet, Ma has been head of tech­ni­cal op­er­a­tions at Sana, which has just opt­ed to change up its man­u­fac­tur­ing build­ing plans in fa­vor of Seat­tle over their orig­i­nal site in Cal­i­for­nia. Sana CEO Steve Harr had proud­ly held Ma up as one of the top R&D ex­ecs at the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER